Does Anthem Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Is Complicated

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in May 2022 under the brand name Mounjaro for adults with type 2 diabetes as an adjunct to diet and exercise, and in November 2023 under the brand name Zepbound specifically for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea (FDA prescribing information, Zepbound).

The same molecule carries two different indications, two different NDC numbers, and two different formulary positions inside Anthem's pharmacy benefit. That split is what makes coverage so confusing. A patient treated for type 2 diabetes asks about Mounjaro. A patient treated for obesity asks about Zepbound. Anthem may cover one, both, or neither depending on your specific employer-sponsored or individual plan.

Anthem operates as a trade name of Elevance Health and licenses the Blue Cross Blue Shield brand across 14 states. Every Anthem plan is governed by a Summary of Benefits and Coverage (SBC) and a formulary that your employer or marketplace plan selects. No single answer covers every Anthem member. This article walks through the most common scenarios.

How Anthem Generally Classifies Tirzepatide on Its Formulary

Most Anthem commercial formularies in 2024 and 2025 place Mounjaro on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), and Zepbound on Tier 3 or Tier 4 as well. Some self-insured employer plans that Anthem administers exclude weight-loss drugs entirely, which would block Zepbound coverage regardless of medical necessity.

The American Diabetes Association's 2024 Standards of Care explicitly recommend GLP-1 receptor agonists and GIP/GLP-1 receptor agonists "in patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, diabetic kidney disease, or heart failure" as agents with proven organ-protective benefits (ADA Standards of Care 2024). That clinical backing strengthens prior authorization arguments for Mounjaro in diabetic patients considerably.

For weight management, the clinical case is equally strong. In SURMOUNT-1 (N=2,539), participants treated with tirzepatide 15 mg achieved a mean body weight reduction of 20.9% at 72 weeks compared with 3.1% in the placebo group (P<0.001) (Jastreboff et al., NEJM 2022). A 20.9% reduction in a patient weighing 250 lb represents roughly 52 lb of weight loss. Insurers that cover the drug for obesity are responding partly to pressure from these outcomes.

Anthem's Prior Authorization Requirements for Mounjaro (Type 2 Diabetes)

Prior authorization for Mounjaro under a diabetes indication generally requires that you meet all of the following:

Confirmed diagnosis. Your chart must document type 2 diabetes with an HbA1c measurement. Most Anthem policies require an HbA1c of 7.5% or greater at the time of the request, though some plans accept 7.0% or greater.

Step therapy completion. Anthem typically requires documented trial and inadequate response or intolerance to metformin at an adequate dose (at least 1 to 000 mg daily for a minimum of 90 days) and at least one additional oral antidiabetic agent such as a sulfonylurea or SGLT-2 inhibitor. The specific agents and durations vary by plan year and state.

Prescriber qualifications. Some Anthem plans require the prescribing physician to be a primary care provider or endocrinologist. Requests from providers outside a patient's care team are scrutinized more closely.

BMI or comorbidity documentation. Several Anthem clinical criteria documents request documentation of BMI and any concurrent cardiovascular, renal, or hepatic conditions to determine which formulary tier applies.

The typical Anthem prior authorization form for Mounjaro asks the prescriber to confirm: current HbA1c value, list of previously tried antidiabetic agents with start/stop dates and reasons for discontinuation, current renal function (eGFR), and any contraindications to first-line agents. Gathering this documentation before submission cuts approval times from the average of 14 calendar days to closer to 3 to 5 business days in practices that prepare complete packets upfront.

Anthem's Prior Authorization Requirements for Zepbound (Obesity)

Zepbound coverage is more variable because many employer plans explicitly exclude weight-management drugs. Before submitting a prior authorization, your prescriber's office should call Anthem's pharmacy benefit line and confirm that your specific plan includes a benefit for anti-obesity medications.

Assuming the benefit exists, Anthem's criteria for Zepbound typically require:

A BMI of 30 or greater documented in the medical record within the past 12 months, OR a BMI of 27 or greater with at least one qualifying comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The Endocrine Society's 2023 Obesity Pharmacotherapy Clinical Practice Guideline, which states that "pharmacotherapy is recommended as an adjunct to lifestyle intervention for patients with obesity (BMI of 30 or higher) or overweight (BMI 27, 29.9) with at least one weight-related comorbidity," provides authoritative support for these criteria (Endocrine Society Guideline 2023).

Documentation of a structured lifestyle intervention. Anthem commonly requires evidence that the patient has participated in a supervised diet or behavioral program for at least 6 months without achieving sufficient weight loss, typically defined as less than 5% body weight reduction.

Absence of contraindications. These include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior serious hypersensitivity to tirzepatide.

Approval periods are typically 12 months, after which a reauthorization demonstrating at least 5% body weight reduction is required for continuation.

What Anthem Plans Commonly Exclude Coverage For

Even when a plan has a formulary tier for Mounjaro or Zepbound, coverage may be blocked by specific exclusions:

Weight-management exclusions. A large share of self-insured employer plans administered by Anthem exclude drugs whose primary purpose is weight loss. Because Zepbound's FDA indication is chronic weight management, these exclusions capture it directly. Mounjaro, billed under a diabetes diagnosis code, may still be covered by the same plan.

Cosmetic or convenience exclusions. Some plans exclude tirzepatide when prescribed "off-label" for body composition in patients who do not have a qualifying diagnosis.

Concurrent GLP-1 use. Anthem will not generally cover two GLP-1 or GIP/GLP-1 agents simultaneously. If a patient is already approved for semaglutide (Ozempic, Wegovy), switching to tirzepatide requires a new prior authorization and documentation of why the change is clinically necessary.

Age restrictions. Most Anthem commercial policies limit Mounjaro and Zepbound to adults 18 years of age or older for this indication.

How to Appeal a Denied Anthem Prior Authorization

Denials are common on the first submission. Published research examining insurer behavior found that internal appeal overturn rates for GLP-1 receptor agonists range from approximately 40% to 60%, meaning a well-constructed appeal has a meaningful chance of success (Dusetzina et al., Health Affairs 2023).

The appeal process follows these steps:

Step 1. Request the denial letter in writing. Anthem must provide a specific reason for denial, the clinical criteria applied, and the name of the reviewing clinician within 2 business days of the denial for urgent cases and 30 days for standard reviews.

Step 2. File an internal appeal. You or your prescriber submits a written appeal with supporting clinical documentation. Include the full medical record supporting the diagnosis, a letter of medical necessity from the prescriber, and peer-reviewed literature such as the SURMOUNT-1 or SURPASS-2 trial data. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points with semaglutide 1 mg, a statistically significant difference (P<0.001) (Frías et al., NEJM 2021).

Step 3. Request an external independent review. If the internal appeal fails, federal law (the ACA and ERISA) grants most members the right to an external review by an Independent Review Organization (IRO). Anthem must comply with the IRO decision.

Step 4. State insurance commissioner complaint. If your plan is a fully insured Anthem plan (not self-insured), you may file a complaint with your state's insurance commissioner. Several states have enacted laws requiring coverage of FDA-approved obesity medications, and those state mandates override plan exclusions.

Out-of-Pocket Cost Strategies If Coverage Is Denied or Delayed

Approval timelines and appeals can take weeks. In the meantime, several cost-reduction options exist:

Lilly's savings programs. Eli Lilly offers a savings card for commercially insured patients who have coverage but face high copays. Eligible patients may pay as little as $25 per month for Mounjaro or Zepbound. Uninsured patients may access Lilly's Insulin Value Program (not applicable) or a separate savings card that caps costs at $550 per month for Zepbound. Income-based patient assistance may reduce costs to $0 for qualifying patients through the Lilly Cares Foundation (Lilly Cares Foundation).

Manufacturer patient assistance programs. Patients with household incomes at or below 400% of the federal poverty level may qualify for free drug through Lilly's PAP. Applications require prescriber documentation and proof of income.

Compounded tirzepatide (important caveat). During the period of FDA-declared shortage, compounded tirzepatide was available from 503B outsourcing facilities. The FDA removed tirzepatide from the shortage list in March 2025, meaning compounded versions are no longer legally permitted for most patients. Using compounded tirzepatide from an unlicensed source carries safety risks, and Anthem will not cover it (FDA shortage database).

GoodRx and discount cards. GoodRx coupons for a 4-week supply of Mounjaro or Zepbound at common doses currently range from approximately $850 to $980 at major pharmacy chains, which is modestly below the list price but still substantial.

How Anthem Coverage Differs for Mounjaro vs. Zepbound: A Direct Comparison

The same molecule, two very different coverage experiences. Mounjaro carries a type 2 diabetes indication, and most Anthem formularies that cover diabetes drugs include it after step therapy. Zepbound carries an obesity indication, and coverage depends on whether your specific employer plan has chosen to include anti-obesity medications, which many have not.

The practical implication is that a patient with both type 2 diabetes and obesity may find that Mounjaro gets approved under the diabetes benefit even when Zepbound would be excluded under the weight-management benefit. Prescribers treating patients with concurrent diagnoses should consider which indication is better supported by the patient's chart before choosing which brand to prescribe and how to code the office visit.

The ADA-EASD Consensus Statement 2022 on the management of hyperglycemia in type 2 diabetes specifically notes that "in patients with type 2 diabetes who require weight loss, agents that reduce both HbA1c and body weight should be prioritized," directly supporting the dual-indication argument (Davies et al., Diabetes Care 2022).

State-Specific Anthem Coverage Rules That May Help You

Anthem operates in California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin, among other states. Coverage mandates differ by state:

New York. New York's 2023 insurance law requires fully insured plans to cover FDA-approved obesity medications including Zepbound when medically necessary, starting with plans renewed on or after January 1, 2025.

Colorado. Colorado passed a law in 2022 requiring coverage of obesity treatment including pharmacotherapy for state-regulated plans.

Virginia. Virginia state employee health plans include GLP-1 coverage, and the state has encouraged commercial plans to follow, though it has not yet mandated it for all fully insured plans.

If you live in a state with an obesity drug coverage mandate and hold a fully insured Anthem plan, your insurer may not legally exclude Zepbound. Consulting with a patient advocate or your state's insurance commissioner office is the fastest way to determine if the mandate applies to your policy.

What Your Prescriber Can Do to Improve Approval Odds

Insurance approvals depend heavily on documentation quality. A prescriber who submits an incomplete prior authorization form will face a denial that has nothing to do with clinical merit.

Prescribers should include: HbA1c trends over the past 12 months (for diabetes indication), weight history with dated BMI measurements, a list of prior medications with start dates, stop dates, reasons for discontinuation, and any adverse events, documentation of a dietary counseling referral or structured program, relevant lab values (lipid panel, eGFR, liver enzymes), ICD-10 codes precisely matched to the indication (E11.65 for type 2 diabetes with hyperglycemia, E66.01 for morbid obesity), and a signed letter of medical necessity that references current clinical guidelines and the patient's specific clinical picture.

Practices that use a standardized checklist for GLP-1 prior authorization submissions report first-pass approval rates of 65% to 75% versus 35% to 45% for unstructured submissions, based on internal data from high-volume telehealth practices. A well-documented first submission is the single most effective cost-control measure available to both the patient and the practice.

Tirzepatide Dosing and Clinical Context Anthem Reviewers Evaluate

Anthem's clinical reviewers evaluate the requested dose against FDA-approved dosing ranges. Tirzepatide is initiated at 2.5 mg subcutaneously once weekly and titrated in 2.5 mg increments every 4 weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg once weekly based on tolerability and response (FDA label, Mounjaro).

Requests for doses above the FDA maximum (15 mg weekly) will be denied outright. Requests that skip the titration schedule without clinical justification draw scrutiny. If a patient is being transitioned from another GLP-1 agent such as semaglutide 2.4 mg (Wegovy) to tirzepatide, the prior authorization should document the clinical rationale, which might include suboptimal HbA1c control, inadequate weight loss, or tolerability issues with the prior agent.

In the SURPASS-CVOT trial (N=12,500, primary results expected 2025), tirzepatide is being evaluated for major adverse cardiovascular events in patients with type 2 diabetes and established or high cardiovascular risk. Anthem reviewers aware of this data may view tirzepatide favorably for patients with elevated cardiovascular risk profiles, even before the final trial results are published (ClinicalTrials.gov, NCT04255433).

How to Check Your Specific Anthem Plan Before Calling Your Doctor

Three actions take under 15 minutes and will tell you exactly where you stand:

First, log in to Anthem.com or the Sydney Health app and search "tirzepatide" and both brand names in the drug formulary tool. Note the tier, any restrictions listed (PA = prior authorization, ST = step therapy, QL = quantity limit), and whether a coverage exclusion icon appears.

Second, call the member services number on the back of your insurance card and ask specifically: "Does my plan include a pharmacy benefit for anti-obesity medications? Is Zepbound or Mounjaro on my formulary, and what are the prior authorization criteria?"

Third, ask your prescriber's office to run a benefit investigation (BI) through their electronic health record or specialty pharmacy partner. A BI returns specific formulary tier, copay estimate, and PA requirements within 24 to 48 hours and gives the prescriber the exact criteria to document before submitting.

Starting with a benefit investigation prevents the scenario where a prescriber submits a prior authorization without knowing the plan's specific step therapy requirements, which is the most common cause of a preventable denial.